Core Insights - The FDA has granted full approval to IMDELLTRA (tarlatamab-dlle) for treating adult patients with extensive stage small cell lung cancer (ES-SCLC) who have disease progression after platinum-based chemotherapy, marking it as a recognized standard of care [1][2][8] - The Phase 3 DeLLphi-304 trial demonstrated that IMDELLTRA reduced the risk of death by 40% and extended median overall survival by more than five months compared to standard chemotherapy [1][3][4] Company Developments - Amgen is committed to advancing IMDELLTRA for earlier stages of small cell lung cancer and earlier lines of therapy, emphasizing its dedication to providing transformative medicines for challenging cancers [2][3] - The safety profile of IMDELLTRA in the DeLLphi-304 trial showed fewer Grade 3 or greater adverse events compared to chemotherapy (54% vs 80%), indicating a favorable safety profile [2][3] Clinical Trial Insights - The DeLLphi-304 study involved 509 patients and was the first global Phase 3 trial to show a significant survival benefit over chemotherapy for ES-SCLC [3][4] - Key secondary outcomes of the trial included progression-free survival and patient-reported outcomes, which further support the efficacy of IMDELLTRA [4] Treatment Landscape - IMDELLTRA targets DLL3, a protein expressed on 85-96% of SCLC cells, making it a promising option for patients with limited treatment alternatives [7][8] - The National Comprehensive Cancer Network (NCCN) has updated its guidelines to include tarlatamab as the only Category 1 preferred treatment option for this patient population [1][2] Future Directions - Amgen's development program for IMDELLTRA includes multiple ongoing clinical trials to evaluate its efficacy in various treatment settings, including combination therapies and earlier lines of treatment [5][6]

Core Viewpoint - The pharmaceutical sector, particularly companies like Eli Lilly and Amgen, has seen significant stock price increases, driven by a shift in investor focus from AI-related stocks to more stable growth stocks in healthcare [2][3][4]. Group 1: Market Trends - The S&P 500 index reached a historical high on October 28, with Eli Lilly's stock rising by 25% and Amgen's by 17% [2]. - AI-related stocks, such as Oracle and Meta, have experienced significant declines, with Oracle down 22% and Meta down 20% [3]. - Investors are reallocating funds from large-cap tech stocks to defensive sectors like healthcare, which are perceived as offering stable growth [3][4]. Group 2: Policy Impact - Concerns over potential drug price reductions under the Trump administration had previously suppressed healthcare stocks, but these fears have begun to ease [4][5]. - A recent agreement between Pfizer and the U.S. government to control drug prices has shifted market perceptions, leading to a more favorable outlook for pharmaceutical companies [4][5]. Group 3: Company Performance - Eli Lilly reported strong earnings for Q3 2025, with its diabetes drug Mounjaro and obesity drug Zepbound exceeding market expectations [5]. - Other companies like Merck and Amgen also reported earnings surpassing market forecasts, contributing to rising stock prices [5]. - Analysts, including Morgan Stanley's Michael Wilson, have a positive outlook on healthcare stocks due to earnings growth, reduced policy uncertainty, and low valuations [5].

Core Viewpoint - The pharmaceutical sector, particularly companies like Eli Lilly and Amgen, has shown significant stock price increases, indicating a shift in investor focus towards stable growth stocks amidst declining AI-related stocks [2][4][5]. Group 1: Market Trends - As of October 28, the S&P 500 index reached a historical high, with Eli Lilly's stock rising by 25% and Amgen's by 17%, reflecting strong performance in the healthcare sector [2][4]. - The decline in AI-related stocks, such as Oracle (down 22%) and Meta (down 20%), has led investors to seek opportunities in defensive stocks like pharmaceuticals [4][5]. - The healthcare sector is viewed as a typical representative of "defensive stocks," expected to provide stable growth [4]. Group 2: Investor Sentiment - Investors are increasingly cautious about large-scale investments in the AI sector, influenced by concerns over potential profit reductions due to intensified competition [5][6]. - Despite the adjustments in AI stocks, investors are not withdrawing from the market, as overall corporate performance remains strong [5][6]. - The healthcare sector, previously overlooked, is now attracting investor interest due to its relatively low valuations [5][6]. Group 3: Policy Impact - A significant change occurred on September 30 when Pfizer reached an agreement with the U.S. government to control drug prices, which is expected to have a limited negative impact on corporate earnings [6]. - The healthcare sector has faced pressure from the Trump administration's drug pricing policies, but recent developments have alleviated some concerns [5][6]. Group 4: Company Performance - Eli Lilly reported strong earnings for Q3 2025, with its diabetes drug Mounjaro and obesity drug Zepbound exceeding market expectations [6]. - Other companies like Merck and Amgen also reported earnings surpassing market forecasts, contributing to further stock price increases [6]. Group 5: Future Outlook - Morgan Stanley's strategist Michael Wilson has a positive outlook on healthcare stocks, citing earnings growth, reduced policy uncertainty, and low valuations as favorable factors [6]. - The healthcare sector's market capitalization is approximately 10%, significantly lower than the nearly 50% share of the tech sector, which may limit its ability to lead the market [7].

We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer discussed. Cramer has recently started to discuss pharmaceutical giant Amgen Inc. (NASDAQ:AMGN) more frequently. Most of his discussions surround the firm’s Repatha drug that aims to reduce cholesterol and prevent adverse cardiovascular events. In a November 11th appearance, the CNBC TV host commented that Amgen Inc. (NASDAQ:AMGN), along with ...

Core Insights - The Dow Jones Industrial Average closed down 557.24 points (-1.18%) on November 17, 2025, influenced by upcoming earnings reports and a backlog of economic data [1] - Anticipation surrounds key corporate earnings from Nvidia, Walmart, and Home Depot, which are expected to provide insights into the AI, technology, and consumer sectors [1] - Delayed economic data, including the September jobs report, is expected to impact perceptions of the U.S. economy and Federal Reserve interest rate decisions [1] Company Performance - Johnson & Johnson, Amgen, and Merck & Co. were among the biggest gainers, reflecting a shift towards defensive or healthcare-related stocks amid market uncertainty, with gains of 2.08%, 1.82%, and 1.11% respectively [2] - American Express led the declines with a drop of 2.37%, attributed to increased net write-off rates in U.S. Consumer Card Member loans, followed by IBM (-2.13%), Salesforce (-1.94%), and Apple (-1.73%) [3]

Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer mentioned in his latest comments. Cramer highlighted the company’s breakthrough medicine, as he remarked: “We had Amgen on the show the other day, announcing a breakthrough in Repatha, its every other week injection squelches cholesterol to a level where it helps prevent heart attacks. Why not go buy that?” Photo by Yiorgos Ntrahas on Unsplash Amgen Inc. (NASDAQ:AMGN) delivers human therapeutics for conditions such as cancer, cardiovascular dise ...

Core Viewpoint - Amgen's stock performance was relatively stable, slightly outperforming the S&P 500 despite a broader market decline of nearly 1.7% on the same day [1]. Group 1: Analyst Commentary - Jim Cramer, a prominent stock analyst, positively highlighted Amgen in his CNBC segment, citing encouraging results from a phase 3 clinical trial of its cholesterol drug Repatha, which significantly reduced the risk of heart attack and stroke [3]. - Scotiabank analyst Louis Chen initiated coverage of Amgen with a sector outperform rating and set a price target of $385 per share [4]. Group 2: Market Reaction - Despite the positive analyst commentary, it is suggested that the positive news regarding Repatha is already reflected in Amgen's stock price, indicating that the market's reaction was appropriate [5]. - Some investors reacted positively to the bullish sentiments from analysts, although it is noted that Amgen was not included in a list of top stock recommendations by The Motley Fool [6][7].

So, let's go a little deeper here on on what's been winning and you you know because we've been talking about it a lot lately of this healthc care trade. Biotech has been rallying after a couple years of underperformance. It has come to life and in a big way as I said monthto date 6.5% for that space.New 52- week high for healthcare. The XBI is coming off a fresh high for this year. Bill, you bought more Amgen which hit a 52- week high today.Carrie owns it in her charitable trust. Tell us more. I I think we ...

Core Insights - The healthcare sector, particularly biotech, is experiencing a significant rally, with a month-to-date increase of 6.5% and new 52-week highs being reached [1][2] - Amgen has reported strong earnings, with earnings per share of 564 compared to 497, driven by positive performance from its cardiovascular drug Repatha [3] - The current market narrative suggests a secular bull market, with healthcare and financials leading the way [2] Biotech Sector Performance - Biotech stocks have been oversold for years, but recent attention is shifting as the market recognizes potential overvaluation in other sectors [5] - UNH has been a catalyst for the healthcare sector, showing a 45% increase since its bottom, which has raised awareness among investors [5] - The sector is benefiting from strategic deals, such as those made by Lilly and Novo, which can improve profitability despite price pressures [6] Company-Specific Insights - Bristol-Myers Squibb is trading at seven times earnings with a 5% dividend yield, while Regeneron is at 14 times earnings with a 6% free cash flow yield, both showing significant price increases in recent months [8][9] - Regeneron has one of the largest drug pipelines in the pharma and biotech industry, contributing to its strong performance [9] - Companies in the sector are expected to leverage AI for better research and efficiency, potentially revolutionizing their operations [10][11] Market Trends - The biotech sector is seeing a resurgence after a prolonged period of underperformance, with several stocks showing upward momentum [12][13] - There is potential for growth in the number of biotech companies gaining investor attention, as more names are expected to emerge as viable investment opportunities [14]

Group 1 - Amgen Inc. is gaining attention for its potential in the healthcare sector, particularly with its cholesterol drug Repatha and weight loss treatments, which could lead to significant outcomes [1][2] - The stock has increased approximately 20% from its lows in late September, driven by strong quarterly results and promising clinical trial outcomes for heart attack prevention [2] - The healthcare sector, including Amgen, is considered undervalued, with analysts noting that it is an opportune time to invest in such stocks [2]